benzyl-dimethyl-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium

412.6 g/mol

412.321554582 g/mol

1VU15B70BP

DTXSID5046984

R - Respiratory system

18.5 Ų

158-163

Soluble

|Danger|H314 (100%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]|P260, P264, P280, P301+P330+P331, P303+P361+P353, P304+P340, P305+P351+P338, P310, P321, P363, P405, and P501|Aggregated GHS information provided by 38 companies from 1 notifications to the ECHA C&L Inventory.

Acute oral LD50 is 295 mg/kg in rat [MSDS]. Benzethonium was not shown to be mutagenic in the AMES Test [MSDS]. In a rat dermal study, there was no evidence of carcinogenic or genotoxic potential. Benzethonium is toxic when orally ingested with 1 g reported to be fatal. The risk of toxicity is related to concentration with cationic detergents. Ingestion may lead to diarrhea, abdominal pain, vomiting, collapse, convulsions, coma. Oral exposure to high concentrations of benzethonium may lead to burns of the mouth, pharynx, and esophagus. To a rarer extent, hemorrhagic gastrointestinal (GI) tract necrosis and peritonitis, bronchospasm, aspiration pneumonitis, hypoxemia, and acute lung injury may develop. CNS depression progressing to coma and shock have been observed with severe ingestion or corrosive GI injury with parenteral administration of cationic detergents.

Pharmacokinetic studies on benzethonium have not been conducted.

Indicated as an antiseptic agent. No therapeutic indications for clinical use.

Benzethonium belongs to the family of compounds known as cationic detergents that act by disrupting lipid bilayers. It demonstrated antitumor activity against cancer cell lines in vitro. The effective dose required to decrease cell viability by 50% after 48 hours (ED50) of benzethonium for FaDu (hypopharyngeal squamous cancer) and C666-1 (nasopharyngeal cancer) cell lines were approximately 3.8 and 5.3 μmol/L, respectively.

Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)

It is reported that percutaneous absorption of benzethonium is clinically insignificant. Benzethonium chloride belongs to the family of|Pharmacokinetic studies on benzethonium have not been conducted.

Pharmacokinetic studies on benzethonium have not been conducted.

Pharmacokinetic studies on benzethonium have not been conducted.

While exact mechanism of benzethonium is not fully understood, it is proposed that benzethonium acts similarly to other structurally-related quaternary ammonium compounds in disrupting cytoplasmic and outer membrane lipid bilayers of microorganisms. The positively charged quaternary nitrogen associates with the polar head groups of acidic membrane phospholipids, followed by the hydrophobic tail interacting with the hydrophobic membrane core. Benzethonium is thought to form mixed-micelle aggregates with hydrophobic membrane components that solubilize membrane and lyse the cells, leading to leakage of cytoplasmic contents. Based on findings in vitro cell assays, its mode of action on cancer cells may involve cancer cell apoptosis via dysregulating mitochondria or rough endoplasmic reticulum (rER). It is proposed that intracellular cationic molecules such as benzethonium will create swelling of the rER and damage the organelle. Ultimately, there is a loss in cell membrane integrity and cytosolic Ca2+ levels increase. Dysregulation of mitochondria and rER leads to the activation of caspase-2, caspase-8, caspase-9, and caspase-3.

Bencetonium Chloride